Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 11/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177331 | 0.84 | SMN1; SMN2 (0.39) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6173956 | 0.84 | CXCR3 (0.40) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6173740 | 0.84 | NPC1 (0.39) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6173373 | 0.82 | SMN1; SMN2 (0.43) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4453125 | 0.82 | MAPT (0.39) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6175669 | 0.80 | PTGS1 (0.54) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4447659 | 0.80 | MAPT (0.41) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4456197 | 0.78 | MAPT (0.40) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4457149 | 0.75 | AGER (0.51) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL10168099 | 0.70 | PDE10A (0.42) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | claimed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | claimed |
| CN-1946391-A | Combinations comprising alpha-2-delta ligands | PFIZER PROD INC (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-6956050-B2 | Imidazole compounds as anti-inflammatory and analgesic agents | PFIZER, INC. (US) | 2005-10-18 | — | — | US | claimed |
| EP-1494667-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | claimed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | claimed |
| WO-2003086390-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | claimed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| CN-1946391-A | Combinations comprising alpha-2-delta ligands | PFIZER PROD INC (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-6956050-B2 | Imidazole compounds as anti-inflammatory and analgesic agents | PFIZER, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1494667-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086390-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | MAPT 4187/4885NPC1 3721/4885RAB9A 4246/4885 |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, PTGES | MAPT 2109/4885NPC1 959/4885RAB9A 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.